CN102762554A - 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 - Google Patents

5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 Download PDF

Info

Publication number
CN102762554A
CN102762554A CN2011800099647A CN201180009964A CN102762554A CN 102762554 A CN102762554 A CN 102762554A CN 2011800099647 A CN2011800099647 A CN 2011800099647A CN 201180009964 A CN201180009964 A CN 201180009964A CN 102762554 A CN102762554 A CN 102762554A
Authority
CN
China
Prior art keywords
compound
compounds
methyl
yloxy
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800099647A
Other languages
English (en)
Chinese (zh)
Inventor
野口洋英
和泉延明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of CN102762554A publication Critical patent/CN102762554A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2011800099647A 2010-02-16 2011-02-09 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇 Pending CN102762554A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30492110P 2010-02-16 2010-02-16
US61/304,921 2010-02-16
PCT/IB2011/050548 WO2011101774A1 (en) 2010-02-16 2011-02-09 (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors

Publications (1)

Publication Number Publication Date
CN102762554A true CN102762554A (zh) 2012-10-31

Family

ID=43904611

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800099647A Pending CN102762554A (zh) 2010-02-16 2011-02-09 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇

Country Status (15)

Country Link
US (1) US20120041026A1 (enExample)
EP (1) EP2536713A1 (enExample)
JP (1) JP2013519722A (enExample)
KR (1) KR20120123089A (enExample)
CN (1) CN102762554A (enExample)
AR (1) AR080172A1 (enExample)
AU (1) AU2011216950A1 (enExample)
CA (1) CA2788656A1 (enExample)
IN (1) IN2012DN06631A (enExample)
MX (1) MX2012008721A (enExample)
SG (1) SG183111A1 (enExample)
TW (1) TW201141856A (enExample)
UY (1) UY33225A (enExample)
WO (1) WO2011101774A1 (enExample)
ZA (1) ZA201206469B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837836A (zh) * 2012-11-21 2015-08-12 拉夸里亚创药株式会社 多晶型物
CN107074837A (zh) * 2014-05-20 2017-08-18 拉夸里亚创药株式会社 苯并异恶唑衍生物盐

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN103702995B (zh) * 2011-05-18 2016-04-13 拉夸里亚创药株式会社 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
AP2015008742A0 (en) 2013-03-20 2015-09-30 Suven Life Sciences Ltd 5-amino quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
CN105873920B (zh) 2013-12-16 2018-06-08 苏文生命科学有限公司 作为5-ht4受体激动剂的吲唑化合物
MX368214B (es) 2015-02-13 2019-09-24 Suven Life Sciences Ltd Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4).
CN117796401A (zh) * 2023-12-25 2024-04-02 江苏万隆化学有限公司 一种含2-羟基-6-氟苯甲酸甲酯中间体抗菌剂的制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090224A1 (en) * 2005-02-25 2006-08-31 Pfizer Japan Inc. Benzisoxazole derivatives

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU217425B (hu) 1991-02-27 2000-01-28 Merrell Dow Pharmaceuticals Inc. Eljárás NMDA antagonista hatású kinolinszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
CA2149918A1 (en) * 1992-11-23 1994-06-09 Mark G. Palermo Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
CZ292379B6 (cs) 1995-09-29 2003-09-17 Glaxo Wellcome Spa Tetrahydrochinolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
IL126003A0 (en) 1996-04-10 1999-04-11 Hoechst Marion Roussel Inc Spiro [cyclopent [b] indole-piperidines] and n-[phenyl-hydrazon intermediates for their preparation both being acetyl cholinesterase and mao inhibitors
CA2252039C (en) 1996-04-12 2002-12-24 Hoechst Marion Roussel, Inc. Isatin derivatives as acetylcholinesterase inhibitors and analgesics
AU717431B2 (en) 1996-07-01 2000-03-23 Schering Corporation Muscarinic antagonists
JP3390179B2 (ja) 1996-08-15 2003-03-24 シェーリング コーポレイション エーテルムスカリン様アンタゴニスト
ATE309215T1 (de) 1996-09-30 2005-11-15 Aventis Pharma Inc Nmda (n-methyl-d-aspartate) antagonists
AU758802B2 (en) 1998-09-30 2003-03-27 Takeda Pharmaceutical Company Limited Drugs for improving vesical excretory strength
WO2002059074A1 (en) 2001-01-26 2002-08-01 Sankyo Company, Limited Benzylamine analogue
CA2440284A1 (en) 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
CA2443108A1 (en) 2001-04-03 2002-10-17 Merck & Co. Inc. N-substituted nonaryl-heterocyclo amidyl nmda/nr2b antagonists
DE60228969D1 (enExample) 2001-07-24 2008-10-30 Richter Gedeon Nyrt
JP3927228B2 (ja) 2003-06-04 2007-06-06 メルク エンド カムパニー インコーポレーテッド Ｎｍｄａ／ｎｒ２ｂ拮抗物質としての３−フルオロ−ピペリジン
GB0316094D0 (en) 2003-07-09 2003-08-13 Neuropharma Sa Acetylcholinesterase dual inhibitors
JP5095388B2 (ja) * 2004-03-03 2012-12-12 ルバンス セラピュティックス インク． ボツリヌストキシンの局所適用及び経皮送達のための組成物及び方法
HU227119B1 (en) 2004-07-29 2010-07-28 Richter Gedeon Nyrt Indole and benzimidazole carboxylic acid amide derivatives and pharmaceutical compositions containing them
HU227000B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Nmda receptor antagonist benzoyl urea derivatives, and pharmaceutical compositions containing them
HUP0401522A2 (en) 2004-07-29 2006-04-28 Richter Gedeon Vegyeszet New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
HU226977B1 (en) 2004-07-29 2010-04-28 Richter Gedeon Nyrt Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
JP4824693B2 (ja) 2004-10-15 2011-11-30 ユニベルシダデ フェデラル ド リオ デ ジャネイロ ピペリジン誘導体、それを含有する薬剤組成物、及び調製方法
US20090124600A1 (en) 2005-04-19 2009-05-14 Layton Mark E N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists
WO2007016357A1 (en) 2005-07-29 2007-02-08 Regents Of The University Of Minnesota Amyloid beta receptor and uses thereof
EP2001463B1 (en) 2006-03-20 2013-07-03 Council of Scientific and Industrial Research A pharmaceutical composition useful as acetyl cholinesterase inhibitors
ES2288406B1 (es) 2006-04-20 2008-12-16 Universidad De Barcelona Compuestos inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
WO2008074816A1 (en) 2006-12-20 2008-06-26 Solvay Pharmaceuticals B.V. Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition
US7605265B2 (en) 2007-01-22 2009-10-20 Biotechnology Research Corporation Ltd. Heterodimers and methods of using them
PL2522668T3 (pl) 2007-05-01 2015-07-31 Concert Pharmaceuticals Inc Związki morfinanu
CN101730706B (zh) 2007-05-11 2015-04-15 生物科技研究有限公司 具有神经保护和增强记忆活性的受体拮抗剂
MX2009014216A (es) 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.
WO2009036235A2 (en) 2007-09-12 2009-03-19 Virginia Tech Intellectual Properties, Inc. Insecticidal carbamates exhibiting species-selective inhibition of acetylcholinesterase (ache)
US8722714B2 (en) 2008-01-16 2014-05-13 The Honk Kong University of Science and Technology Oxazolidine derivatives as NMDA antagonists
EA014100B1 (ru) 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
CN101440061B (zh) 2008-04-08 2010-12-08 温州医学院 一类具有抑制乙酰胆碱酯酶活性的芳基吡啶酮类衍生物
WO2009129181A1 (en) 2008-04-14 2009-10-22 Concert Pharmaceuticals Inc. Propanediol-dicarbamate derivatives
CN102762207A (zh) 2008-05-09 2012-10-31 爱莫里大学 用于治疗神经精神疾患的nmda受体拮抗剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006090224A1 (en) * 2005-02-25 2006-08-31 Pfizer Japan Inc. Benzisoxazole derivatives

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104837836A (zh) * 2012-11-21 2015-08-12 拉夸里亚创药株式会社 多晶型物
CN107074837A (zh) * 2014-05-20 2017-08-18 拉夸里亚创药株式会社 苯并异恶唑衍生物盐
CN108329305A (zh) * 2014-05-20 2018-07-27 拉夸里亚创药株式会社 苯并异恶唑衍生物盐
CN107074837B (zh) * 2014-05-20 2020-07-28 拉夸里亚创药株式会社 苯并异恶唑衍生物盐

Also Published As

Publication number Publication date
UY33225A (es) 2011-09-30
US20120041026A1 (en) 2012-02-16
AU2011216950A1 (en) 2012-08-23
CA2788656A1 (en) 2011-08-25
KR20120123089A (ko) 2012-11-07
TW201141856A (en) 2011-12-01
AR080172A1 (es) 2012-03-21
MX2012008721A (es) 2012-08-17
SG183111A1 (en) 2012-09-27
WO2011101774A1 (en) 2011-08-25
IN2012DN06631A (enExample) 2015-10-23
JP2013519722A (ja) 2013-05-30
EP2536713A1 (en) 2012-12-26
ZA201206469B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
CN102762554A (zh) 5-ht4受体的部分激动剂(r)-4-((4-((4-(四氢呋喃-3-基氧基)苯并[d]异*唑-3-基氧基)甲基)哌啶-1-基)甲基)四氢-2h-吡喃-4-醇
JP4351053B2 (ja) ジヒドロキシピリミジンカルボキサミド系ｈｉｖインテグラーゼ阻害薬
CN102143955B (zh) 作为代谢型谷氨酸受体调节剂的3-氮杂二环[3.1.0]己烷衍生物
US20230265116A1 (en) Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
IL275058B2 (en) Sulfonylurea derivatives as modulators of the NLRP3 inflammasome
WO2009050227A1 (en) Pyridazine derivatives for inhibiting beta amyloid peptide production
JP2021506848A (ja) Ｅ３ユビキチンリガーゼ部分を持つｅｇｆｒを有する二官能性阻害剤
KR20110086769A (ko) 베타 세크레타제 억제제로서의 락탐
US20040132710A1 (en) Lactams as tachkinin antagonists
WO2022174882A1 (en) 5-membered heterocyclyl carbamate derivatives as dual lpa receptor 1 and lpa receptor 2 inhibitors
CA3198096A1 (en) Aryl derivatives for treating trpm3 mediated disorders
JP6626965B2 (ja) ピラゾロ［１，５−ａ］ピリミジン−３−カルボキシアミドの環状エーテル誘導体
JP5947897B2 (ja) Ｎ−ピペリジン−４−イル誘導体
AU2011336217B2 (en) KAT II inhibitors
WO2011143155A1 (en) Substituted n-heteroaryl tetrahydro-isoquinoline derivatives, preparation and therapeutic use thereof
DE602004003914T2 (de) Für die therapie geeignete triazolverbindungen
WO2022167867A1 (en) Substituted cyclic modulators of protein phosphatase 2a (pp2a) and methods using same
IL300792A (en) Compounds that inhibit ototaxin
RU2809257C2 (ru) Новые гетероциклические соединения
JP2023544037A (ja) ビヘテロアリール化合物およびその結晶形態を調製するための方法
TW202547501A (zh) Ｃｕｇ重複ｒｎａ與ｍｂｎｌ蛋白質之結合阻礙化合物及醫藥
TW202530205A (zh) 經取代之芳基磺醯胺及其組合物及用途
CN121263410A (zh) 作为sik抑制剂的苯并呋喃衍生物以及其用途
KR20190075072A (ko) 4,4a,5,7-테트라히드로-3H-푸로[3,4-b]피리디닐 화합물
HK1222391B (zh) 氧代喹唑啉基-丁酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121031